- Home
- PYN vs SCYX Comparison
PYN vs SCYX Comparison
Compare PYN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- SCYX
- Stock Information
- Founded
- PYN 2002
- SCYX 1999
- Country
- PYN United States
- SCYX United States
- Employees
- PYN N/A
- SCYX N/A
- Industry
- PYN Investment Managers
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- SCYX Health Care
- Exchange
- PYN Nasdaq
- SCYX Nasdaq
- Market Cap
- PYN 30.1M
- SCYX 28.5M
- IPO Year
- PYN N/A
- SCYX 2014
- Fundamental
- Price
- PYN $5.33
- SCYX $0.69
- Analyst Decision
- PYN
- SCYX
- Analyst Count
- PYN 0
- SCYX 0
- Target Price
- PYN N/A
- SCYX N/A
- AVG Volume (30 Days)
- PYN 19.9K
- SCYX 127.6K
- Earning Date
- PYN 01-01-0001
- SCYX 08-07-2025
- Dividend Yield
- PYN 5.07%
- SCYX N/A
- EPS Growth
- PYN N/A
- SCYX N/A
- EPS
- PYN N/A
- SCYX N/A
- Revenue
- PYN N/A
- SCYX $2,630,000.00
- Revenue This Year
- PYN N/A
- SCYX $463.61
- Revenue Next Year
- PYN N/A
- SCYX $310.80
- P/E Ratio
- PYN N/A
- SCYX N/A
- Revenue Growth
- PYN N/A
- SCYX N/A
- 52 Week Low
- PYN $4.84
- SCYX $0.66
- 52 Week High
- PYN $6.60
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- PYN 58.56
- SCYX 37.15
- Support Level
- PYN $5.25
- SCYX $0.67
- Resistance Level
- PYN $6.13
- SCYX $0.75
- Average True Range (ATR)
- PYN 0.10
- SCYX 0.04
- MACD
- PYN 0.01
- SCYX 0.00
- Stochastic Oscillator
- PYN 13.98
- SCYX 25.54
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.